C. Rivard

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
C J Rivard, C. J. Rivard, Chris Rivard, C Rivard, Christopher J Rivard, Christopher Rivard, Chris J. Rivard, Christopher J. Rivard, Chris J Rivard, C.j. Rivard, C. Rivard
Publication record
205 papers · 8,628 citations · H-index 48

PAPERS

Indoleamine 2,3-dioxygenase-1 expression in non-small-cell lung cancer: analyses of prevalence, clinical correlations and prognostic impact in 2 large patient cohorts
20251 citationsauthor #10
Role of Lactate in the Regulation of Transcriptional Activity of Breast Cancer-Related Genes and Epithelial-to-Mesenchymal Transition Proteins: A Compassion of MCF7 and MDA-MB-231 Cancer Cell Lines
20236 citationsauthor #6
Role of Lactate in the Regulation of Transcriptional Activity of Breast Cancer- 1 Related Genes and Epithelial-to-Mesenchymal Transition Proteins: A Comparison 2 of MCF7 and MDA-MB-231 Cancer Cell Lines
20230 citationsauthor #7
Protein Expression of immune checkpoints STING and MHCII in small cell lung cancer
202216 citationsauthor #2
Expression patterns and prognostic relevance of subtype‐specific transcription factors in surgically resected small‐cell lung cancer: an international multicenter study
202270 citationsauthor #18
Loss of STING expression is prognostic in non–small cell lung cancer
202223 citationsauthor #4
EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC.
202111 citationsauthor #8
OA06.06 Clinical/Biomarker Data for Neoadjuvant Atezolizumab in Resectable Stage IB-IIIB NSCLC: Primary Analysis in the LCMC3 Study
202136 citationsauthor #13
Characterization of Tumor-Associated Macrophages and the Immune Microenvironment in Limited-Stage Neuroendocrine-High and -Low Small Cell Lung Cancer
202132 citationsauthor #2
P68.12 Inter-Tumor Heterogeneity of CD44 Expression in Non-Small Cell Lung Cancers / EGFR Mutated Lung Adenocarcinomas
20210 citationsauthor #2
Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes
202124 citationsauthor #9
Comprehensive Immune Profiling of Medullary Thyroid Cancer
202047 citationsauthor #5
Small Cell Lung Cancer Neuroendocrine Subtypes are Associated with Different Immune Microenvironment and Checkpoint Molecule Distribution
20200 citationsauthor #2
Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer.
20205 citationsauthor #9
Multi-institutional prospective validation of prognostic mRNA signatures in early stage squamous lung cancer (Alliance).
202033 citationsauthor #16
Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution
202075 citationsauthor #2
Fructose contributes to the Warburg effect for cancer growth
2020122 citationsauthor #5
Fructose tolerance test in obese people with and without type 2 diabetes
20207 citationsauthor #2
Role of mTOR as an essential kinase in SCLC.
202017 citationsauthor #7
Fructose contributes to the Warburg effect for cancer growth
20200 citationsauthor #5
FGFR1 Is Critical for RBL2 Loss–Driven Tumor Development and Requires PLCG1 Activation for Continued Growth of Small Cell Lung Cancer
202016 citationsauthor #3
OA13.01 SPECS2 Lung Cancer Consortium Prospective Multicenter Validation of Prognostic Signature for Early Stage Squamous Lung Cancer
20190 citationsauthor #13
P1.12-05 Microenvironment Characterization of Small Cell Lung Cancer Xenografts Implanted in Hematopoietic Humanized Mice
20192 citationsauthor #6
P1.12-09 RNA Sequencing in Small Cell Lung Carcinoma Reveals Change in Neuroendocrine Pattern in Primary Tumor Versus Lymph Node Metastases
20190 citationsauthor #7
Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance
20199 citationsauthor #14
Abstract 4550: Correlations between tumor mutation burden, inflammatory profile and histological characteristics of tumor microenvironment in early-stage squamous cell lung carcinoma
20190 citationsauthor #7
Correlation of PD‐L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early‐Stage Squamous Cell Lung Carcinoma
201977 citationsauthor #19
Abstract A043: NaPi2b expression in a large surgical non-small cell lung cancer cohort
20190 citationsauthor #7
Abstract 4025: STEAP4 ISH and IHC diagnostics for Tarloxotinib activation in EGFR/HER2 mutant cancers
20195 citationsauthor #4
Abstract 2202: Tarloxotinib exhibits potent activity in NRG1 fusion and rearranged cancers
20197 citationsauthor #4
EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis.
201944 citationsauthor #5
Comparative expression analysis in small cell lung carcinoma reveals neuroendocrine pattern change in primary tumor versus lymph node metastases.
201915 citationsauthor #8
The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression.
201843 citationsauthor #5
P1.04-23 Expression of Emerging Immunotherapy Targets in Early-Stage Squamous Lung Carcinoma
20180 citationsauthor #14
P2.09-24 MERS67 is a Novel anti-NaPi2b Antibody and Demonstrates Differential Expression Patterns in Lung Cancer Histologic Subtypes
20182 citationsauthor #7
Abstract 3636: The immune checkpoint, HVEM, is associated with PDL1 expression in lung cancer cell lines
20180 citationsauthor #4
Fructose increases risk for kidney stones: potential role in metabolic syndrome and heat stress
201855 citationsauthor #11
P2.04-15 Heterogeneity and Correlation Between Immune Markers in Lung Cancers: Analysis of Treatment-Naïve Lesions
20181 citationsauthor #5
Abstract 3637: Expression of an immune checkpoint- Poliovirus Receptor (PVR) in small cell lung cancer
20180 citationsauthor #5
Tumor autoantibodies (TAAs) panel can improve the accuracy of early diagnosis in lung cancer presenting with ground-glass nodules (GGNs) in Chinese population
20184 citationsauthor #4
CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer
201839 citationsauthor #9
A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines
20186 citationsauthor #2
Comparison the anti-tumor effect of pyrotinib, afatinb and T-DM1 in lung cancer organoids and PDX models with HER2 mutation.
20185 citationsauthor #4
P2.04-13 The Immune Checkpoint, HVEM Contribute to Immune Escape in Non Small Cell Lung Cancer of Lacking PDL1 Expression
20180 citationsauthor #3
P3.12-13 Expression of the Immune Checkpoint Axis-PVR/TIGIT in Small Cell Lung Cancer
20188 citationsauthor #13
Upregulation of CD80 on glomerular podocytes plays an important role in development of proteinuria following pig‐to‐baboon xeno‐renal transplantation – an experimental study
201837 citationsauthor #1
P2.09-01 Tumor-Associated Immune Cell Infiltration Patterns in Early Stage Squamous Lung Carcinoma
20180 citationsauthor #7
Effects of fructose-containing sweeteners on fructose intestinal, hepatic, and oral bioavailability in dual-catheterized rats
20189 citationsauthor #2
Evaluation of CD73 in lung cancer.
20170 citationsauthor #3
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer
2017696 citationsauthor #15
miRNA for Early Detection of Lung Cancer: Comparison of Tissue, Sputum and Plasma Signatures
20172 citationsauthor #1
Abstract 4583: Heterogeneity in immune biomarker expression: Detailed analysis of a case with SCLC transformation after EGFR-TKI treatment
20170 citationsauthor #6
MA 05.14 Differential Expression of IFN-Stimulating DNA Sensors STING and cGAS in Lung Cancer Subtypes
20170 citationsauthor #5
EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study
201716 citationsauthor #9
P1.05-001 Creation and Early Validation of Prognostic miRNA Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium: Topic: Translational Research and Biomarkers
20171 citationsauthor #22
Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.
201729 citationsauthor #3
MA15.11 Acquired Resistance Mechanisms to EGFR Kinase Inhibitors Alter PD-L1 Expression Status in Lung Cancer
20172 citationsauthor #3
P2.03b-035 EGFR FISH as Potential Predictor of Necitumumab Benefit with Chemotherapy in Squamous NSCLC: Subgroup Analyses from SQUIRE: Topic: Biomarkers
20170 citationsauthor #3
Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status
201714 citationsauthor #5
PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes
201753 citationsauthor #3
Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms
201730 citationsauthor #2
Primary Double‐Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench
201729 citationsauthor #3
P1.05-027 Novel Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma: A Study by the SPECS Lung Consortium: Topic: Translational Research and Biomarkers
20170 citationsauthor #22
Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment‐Naïve Lesions
201726 citationsauthor #7
MA 13.02 Comprehensive Genetic Analysis Related to PD-L1 Expression in Early-stage Lung Squamous Cell Carcinoma
20170 citationsauthor #16
Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines
201715 citationsauthor #7
LAG‐3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD‐1/PD‐L1 and Tumor‐Infiltrating Lymphocytes
2017248 citationsauthor #4
OA19.01 A Standardized and Validation of Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium
20170 citationsauthor #22
MHC class II expression in lung cancer.
2017104 citationsauthor #3
Abstract 2626: Expression of human poliovirus receptor, an immune checkpoint biomarker in lung cancer
20170 citationsauthor #4
PS06.01 CD44 Confers EMT Phenotypic Change Following Resistance to EGFR-TKIs in Lung Cancer: Topic: Pathology
20171 citationsauthor #7
Seven-microRNA panel for lung adenocarcinoma early diagnosis in patients presenting with ground-glass nodules
201717 citationsauthor #6
Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation
201721 citationsauthor #6
PD‐L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer
2017123 citationsauthor #11
Acetazolamide and N-acetylcysteine in the treatment of chronic mountain sickness (Monge's disease).
201723 citationsauthor #9
Uric acid in metabolic syndrome: From an innocent bystander to a central player.
2016360 citationsauthor #6
Heat stress, hydration and uric acid: a cross-sectional study in workers of three occupations in a hotspot of Mesoamerican nephropathy in Nicaragua
2016148 citationsauthor #6
Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma
201620 citationsauthor #6
MHC class II in lung cancer
20161 citationsauthor #4
Lymphocyte‐activation gene‐3, an important immune checkpoint in cancer
2016167 citationsauthor #2
Heterogeneity in Tumors and Resistance to EGFR TKI Therapy-Letter.
20166 citationsauthor #2
Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy‐Naive Isogenic Lung Cancer Lesions with EGFR Mutation
201611 citationsauthor #7
LAG 3/MHC 2 and PD 1/PD L1 expression in non-small cell lung cancer patients.
20163 citationsauthor #5
ORAL01.01: A Prospective, Multi‐Institutional Assessment of Four Assays for PD‐L1 Expression in NSCLC by Immunohistochemistry: Topic: Pathology
201611 citationsauthor #15
PS01.20: Immune Checkpoints Expression in Small Cell Lung Cancer Lines: Topic: Pathology
20161 citationsauthor #3
Opposing Activity Changes in AMP Deaminase and AMP-Activated Protein Kinase in the Hibernating Ground Squirrel
201545 citationsauthor #10
Fat oxidation is activated in liver during hibernation.
20150 citationsauthor #10
Abstract 558: Correlations of FGFR1 with ligand signaling in small-cell lung cancer
20150 citationsauthor #5
Bioactivity-Guided Identification of Botanical Inhibitors of Ketohexokinase
201519 citationsauthor #7
Fat storage syndrome in Pacific peoples: a combination of environment and genetics?
201414 citationsauthor #4
194PPREVALENCE AND PROGNOSTIC SIGNIFICANCE OF SODIUM-DEPENDENT PHOSPHATE TRANSPORTER 2B (NAPI2B) PROTEIN EXPRESSION IN NON-SMALL CELL LUNG CANCER (NSCLC).
201411 citationsauthor #11
CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance
201463 citationsauthor #5
Uric acid‐dependent inhibition of AMP kinase induces hepatic glucose production in diabetes and starvation: evolutionary implications of the uricase loss in hominids
2014179 citationsauthor #8
Temporal and spatial increase of reactive nitrogen species in the kainate model of temporal lobe epilepsy.
201450 citationsauthor #3
Serum uric acid predicts vascular complications in adults with type 1 diabetes: the coronary artery calcification in type 1 diabetes study
201452 citationsauthor #3
Serum Uric Acid and Hypertension in Adults: A Paradoxical Relationship in Type 1 Diabetes
201417 citationsauthor #7
Serum uric acid and insulin sensitivity in adolescents and adults with and without type 1 diabetes.
201435 citationsauthor #6
Rituximab in idiopathic nephrotic syndrome: does it make sense?
201412 citationsauthor #4
Endogenous fructose production and fructokinase activation mediate renal injury in diabetic nephropathy.
2014141 citationsauthor #13
nephropathy in the eNOS-deficient mouse Nicorandil as a novel therapy for advanced diabetic
20130 citationsauthor #11

TIMELINE

1979 1 citations

1982 93 citations

1984 40 citations

1986 100 citations

1987 0 citations

1988 18 citations

1989 59 citations

1990 77 citations

1991 131 citations

1992 17 citations

1993 28 citations

1994 8 citations

1995 118 citations

1996 126 citations

1998 14 citations

1999 4 citations

2001 88 citations

2003 94 citations

2004 49 citations

2005 72 citations

2006 9 citations

2007 110 citations

2008 129 citations

2009 436 citations

2010 490 citations

2011 462 citations

2012 1,095 citations

2013 1,038 citations

2014 574 citations

2015 64 citations

2016 728 citations

2017 1,450 citations

2018 209 citations

2019 159 citations

2020 322 citations

2021 103 citations

2022 109 citations

2023 6 citations

2025 1 citations

Unknown 4 citations

C. Rivard

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT